Tuberculosis vaccines in the era of Covid-19 - what is taking us so long?
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 35427852.
- Also identified by DOI 10.1016/j.ebiom.2022.103993 and PMC identifier 9002045.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The Mycobacterium bovis BCG vaccine was first used in 1921, but has not controlled the global spread of tuberculosis (TB). There are still no new licensed tuberculosis vaccines, although there much active research and a vaccine development pipeline, with vaccines designed to prevent infection, prevent disease, or accelerate TB treatment. These vaccines are of different types, and designed to replace BCG, or to boost immunity following BCG vaccination. This viewpoint discusses why, when it has been possible to develop new vaccines for SARS-CoV-2 so quickly, it is taking so long to develop new tuberculosis vaccines.
Medical subject headings
- COVID-19
- Mycobacterium bovis
- Mycobacterium tuberculosis
- Tuberculosis Vaccines